As noted above, current PAH therapies are focused mainly on vasodilation either by enhancing vasodilator mechanisms such as the prostacyclin-cAMP pathway and the NO-cGMP pathway or by inhibiting vasoconstrictor mechanisms such as endothelin-1 and Ca2+ entry pathways [8,9]. Here, EDN1 is linked to pulmonary arterial hypertension.